Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MET642 · 1 trial · 1 indication
Incidences of treatment-emergent adverse events
Incidences of clinically significant changes in vital signs
Incidences of clinically significant changes in laboratory tests
Incidences of clinically significant changes in ECGs
| Arm | Type | Description |
|---|---|---|
| MET642 high dose | EXPERIMENTAL | - |
| MET642 low dose | EXPERIMENTAL | - |
| MET642 Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| MET642 | DRUG | MET642 active treatment |
| Placebo | DRUG | Placebo comparator |
Inclusion Criteria: * Diagnosis of NASH via biopsy, magnetic resonance elastography (MRE), or transient elastography (TE, FibroScan) * Liver fat content ≥ 10% as measured by magnetic resonance imaging-proton density fat fraction (MRI-PDFF). Exclusion Criteria: * History of significant liver disea...
MET642 is an investigational small molecule being developed for the treatment of NASH, or nonalcoholic steatohepatitis. It is a metabolic therapeutic that has been studied in a Phase 2 clinical trial. The drug is not approved and remains in clinical development.
MET642 is a small molecule designed to treat NASH, a form of fatty liver disease. Its specific molecular target has not been disclosed in available information. The drug is being evaluated for its ability to address the underlying metabolic drivers of the condition.
MET642 is being developed by Equillium, Inc., a biopharmaceutical company. Equillium is conducting clinical research on this investigational drug for the treatment of NASH. The company's stock is traded under the ticker symbol EQ.
MET642 is in Phase 2 clinical development. A Phase 2 study evaluating the drug in patients with NASH has been completed. The drug is investigational and has not received FDA approval for any indication.
MET642 has been studied in one completed Phase 2 clinical trial, identified as NCT04773964. This randomized, double-blind, placebo-controlled study enrolled 215 participants with NASH in the United States. The trial included adults aged 18 years and older.
MET642 is the primary name for this investigational drug. No alternative names have been reported for this asset. It is being studied specifically for the treatment of NASH and is not known to be identical to any other approved or investigational medication.